Iptacopan in IgA Nephropathy — Final 24-Month Data | Synapse
April 1, 2026
Iptacopan in IgA Nephropathy — Final 24-Month Data
Key Points
To evaluate the efficacy of iptacopan in slowing kidney function decline in IgA nephropathy patients.
Clinical trial comparing iptacopan therapy with placebo.
Assessment of kidney function over 24 months.
Iptacopan therapy resulted in a significantly slower decline in kidney function compared to placebo.
Abstract
Iptacopan therapy led to a significantly slower decline in kidney function than placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).